Is romosozumab an option in a patient who has completed 2 years of teriparatide therapy and has a fracture while on denosumab?  

Romosozumab would be an excellent option in this setting. Although both teriparatide and romosozumab are anabolic agents, they have different MOAs and there is no cumulative time limit of therapy as there would be in the case of additional therapy with abaloparatide. At the completion of therapy wit...